Clinical Trial Update: Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of odanacatib (MK-0822) in involutional osteoporosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoporosis Postmenopausal | Phase 2 | Status: COMPLETED | Results posted: 2017-03-13